Athira Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATHA Nasdaq 2830 www.athira.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Athira Pharma, Inc.

Athira Pharma Insider Ups Holding By 111% During Year - Dec 18th, 2024 12:19 pm
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND - Dec 6th, 2024 10:30 pm
Athira exploring strategic alternatives after Alzheimer’s failure - Nov 8th, 2024 9:50 am
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - Nov 7th, 2024 9:05 pm
US Penny Stocks: November 2024's Top Picks To Consider - Nov 4th, 2024 5:05 pm
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - Oct 22nd, 2024 11:00 am
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - Sep 17th, 2024 1:00 pm
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More - Sep 5th, 2024 3:15 pm
Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial - Sep 4th, 2024 3:33 pm
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - Sep 4th, 2024 3:32 pm
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks - Sep 4th, 2024 12:48 pm
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease - Sep 3rd, 2024 8:01 pm
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? - Aug 23rd, 2024 1:40 pm
Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? - Aug 7th, 2024 1:40 pm
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates - Aug 1st, 2024 8:05 pm
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024 - Jul 31st, 2024 12:05 pm
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Jul 10th, 2024 12:51 pm
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease - Jul 9th, 2024 11:00 am
retail investors who own 35% along with institutions invested in Athira Pharma, Inc. (NASDAQ:ATHA) saw increase in their holdings value last week - Jun 30th, 2024 2:42 pm
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients - Jun 12th, 2024 11:00 am